Company intelligence / Profile preview

Rhomed

Albuquerque, New Mexico, United States

Ownership: Private
Development stage: Other

Overview

RhoMed was a biotechnology company specializing in the development of radiopharmaceuticals for diagnostic imaging and therapy. The company's core expertise lay in its proprietary technology for labeling monoclonal antibodies and peptides with Technetium-99m, a widely used medical radioisotope. Its lead candidates included P2045 for the imaging of small cell lung cancer and other agents for detecting infections and deep vein thrombosis. RhoMed was acquired by Schering AG in 2001 to bolster Schering's nuclear medicine and oncology portfolio, which later became part of Bayer.

Therapeutic areas: OncologyCardiovascularInfectious Diseases
Modalities: RadiopharmaceuticalPeptidesMonoclonal antibody
Industry: Biotech

Partnerships

Schering AG

Beyond the preview

Go deeper on Rhomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhomed.

Explore the full profile